Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years

  • 38 Accesses

  • 33 Citations

Abstract

In order to evaluate the combination of immunochemotherapy with mitomycin C (MMC), futraful (FT) and PSK, as an adjuvant to surgery for curatively resected gastric cancer, a randomized controlled study by the sealed envelope method was performed with the participation of 97 hospitals in the Kyushu and Chugoku districts of Japan. The MMC+FT+ PSK group showed a significant increase in 5 year survival from the other groups (p<0.05). Moreover the survival rate was significantly higher in the MMC+FT+PSK group than in the MMC+FT group (p<0.01). According to the analysis on stratification, the MMC+FT+PSK group showed the best survival rate in cases with positive lymph node metastases, positive serosal invasion and positive lymph node metastases plus serosal invasion, and in cases of undifferentiated carcinoma by histological type and in those with a preoperative positive PPD reaction (p<0.01 or p<0.05). Thus, the combination of MMC, FT and PSK was indicated to be useful as an adjuvant immunochemotherapy for those patients with gastric cancer submitted to curative resection.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Inokuchi K, Hattori T, Taguchi T, Abe O, Ogawa N. Postoperative adjuvant chemotherapy for gastric cancer. Analysis of data on the 1805 patients followed for 5 years. Cancer 1984; 53: 2393–2397.

  2. 2.

    Hattori T, Inokuchi K, Taguchi T, Abe O, Inoue K, Kondo T, Kikuchi K, Kasai Y. Postoperative longterm adjuvant chemotherapy for gastric cancer: Second study of five-year survival. In: Ishigami J, ed. Recent advances in chemotherapy. Anticancer Section II. Tokyo: Univ. of Tokyo Press 1985; 1270–1271.

  3. 3.

    Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 1975; 11: 127–145.

  4. 4.

    Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K, Krestin (PSK). Cancer Treatment Reviews 1984; 11: 131–155.

  5. 5.

    Kano T, Abe Y, Hiramoto Y, Inoue F, Shiraishi M, Tamada R, Kumashiro R, Kodama Y, Inokuchi K. Effect of postoperative long-term cancer chemotherapy (PLCC) on gastric cancer patients with peritoneal dissemination. Gan to Kaguku-Ryoho 1981; 8: 1418–1424. (English Abst.)

  6. 6.

    Hattori T, Niimoto M, Nakano A, Oride M, Takiyama W, Nishimawari K. Postoperative long-term adjuvant immunochemotherapy with Mitomycin C, PSK and FT-207 in gastric cancer patients. Jpn J Surg 1979; 9: 110–117.

  7. 7.

    Niimoto M, Hattori T, Ito I, Tamada R, Inokuchi K, Orita K, Furue H, Ogawa N, Toda T, Furusawa M, Koga S, Hashimoto S, Kondo T, Fujimoto S, Sugimachi Y, Abe O, Oya M. Levamisole in postoperative adjuvant immunochemotherapy for gastric cancer. A randomized controlled study of the MMC+Tegafur regimen with or without Levamisole. Report 1. Cancer Immunol Immunother 1984; 18: 13–18.

  8. 8.

    Yamamura Y, Yasue M, Nakazato H, Ota K. A controlled study of surgical adjuvant chemotherapy with FT-207 and OK-432 for advanced stomach cancer. The Fourth Study. Gan to Kagaku-Ryoho 1985; 12: 541–548. (English Abst.)

  9. 9.

    Nakajima T, Inokuchi K, Hattori T, Inoue K, Taguchi T, Kondo T, Abe O, Kikuchi K, Tanabe T, Ogawa N. A multi-institutional study on postoperative adjuvant immunochemotherapy for gastric cancer. Gan to Kagaku-Ryoho 1985; 12: 1850–1863. (English Abst.)

Download references

Author information

Correspondence to Minoru Niimoto MD.

Additional information

The Co-operative Study Group of Surgical Adjuvant Chemotherapy for Gastric Cancer

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Niimoto, M., Hattori, T., Tamada, R. et al. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. The Japanese Journal of Surgery 18, 681–686 (1988). https://doi.org/10.1007/BF02471530

Download citation

Key Words

  • gastric cancer
  • adjuvant immunochemotherapy
  • mitomycin C
  • futraful
  • PSK